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ABSTRACT: Coxsackievirus A24 variant (CVA24v) and human adenovirus
37 (HAdV-37) are leading causative agents of the severe and highly contagious
ocular infections acute hemorrhagic conjunctivitis and epidemic keratocon-
junctivitis, respectively. Currently, neither vaccines nor antiviral agents are
available for treating these diseases, which affect millions of individuals
worldwide. CVA24v and HAdV-37 utilize sialic acid as attachment receptors
facilitating entry into host cells. Previously, we and others have shown that
derivatives based on sialic acid are effective in preventing HAdV-37 binding
and infection of cells. Here, we designed and synthesized novel pentavalent
sialic acid conjugates and studied their inhibitory effect against CVA24v and
HAdV-37 binding and infection of human corneal epithelial cells. The
pentavalent conjugates are the first reported inhibitors of CVA24v infection and proved efficient in blocking HAdV-37 binding.
Taken together, the pentavalent conjugates presented here form a basis for the development of general inhibitors of these highly
contagious ocular pathogens.
Every year millions of individuals around the world areaffected by acute conjunctivitis.1,2 The disease can be
caused by allergens, chemicals, or underlying systemic disease;
however, the majority of cases is caused by viruses and
bacteria.1−3 Viral conjunctivitis is estimated to cause up to 80%
of all cases of acute conjunctivitis.1 Acute hemorrhagic
conjunctivitis (AHC) and epidemic keratoconjunctivitis
(EKC) are severe and highly contagious forms of viral
conjunctivitis.4,5 AHC is characterized by a sudden onset of
ocular pain, foreign body sensation, excessive lacrimation,
keratitis, and conjunctivitis.6 Many of these symptoms are also
shared with EKC, and it is difficult to differentiate these
diseases in a clinical setting.7 The infections are generally self-
limited, resolving in 1−2 weeks but can become potentially
life-threatening in immunocompromised individuals.5,8,9 AHC
spreads rapidly within communities, affecting up to 50% of the
population. As a result, outbreaks can exhaust healthcare
resources of affected regions and severely disrupt the
economy.5,10 To date, neither antiviral agents nor vaccines
are available for treating or preventing AHC or EKC.
AHC is predominantly caused by two members of the
Picornaviridae family, coxsackievirus A24 variant (CVA24v)
and enterovirus 70 (EV70).11 CVA24v has been reported as
the principal etiological agent responsible for >10 million cases
of AHC worldwide during the last decades, including two
pandemics and numerous recurring outbreaks.10,12 To facilitate
attachment and subsequent entry, members of the Picornavir-
idae engage a range of different cellular receptors including
coxsackie and adenovirus receptor (CAR), decay accelerating
factor (DAF, CD55), low density lipoprotein receptor (LDL-
R), human P-selectin glycoprotein ligand-1 (PSGL-1), heparan
sulfate, integrins, intercellular adhesion molecule-1 (ICAM-1),
and glycan-containing receptors terminating in 5-N-acetylneur-
aminic acid (sialic acid).13−17 EV70 is reported to bind DAF
and glycans that terminate in α2,3-linked sialic acid,13,16 while
CVA24v binds to α2,3- and α2,6-linked sialic acids via
pentameric binding sites.14,15,18 In addition, engagement of the
ICAM-1 receptor is essential for coxsackievirus A24 infection,
including nonvariant and variant strains of the virus. However,
the virulence and pandemic nature of the variant, AHC-causing
strain seems to be linked to an enhanced ability to bind sialic
acid.19 This adaptation has been suggested to enable efficient
attachment of CVA24v to corneal and conjunctival cells15 and
thereby enhance the transmission of viral progeny.19
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EKC is contracted by millions of individuals worldwide
every year.20 The disease is caused by members of the
Adenoviridae family (HAdV-8, -19, -37, -53, -56, and -64), with
HAdV-37 serving as a leading causative agent.21 EKC-causing
human adenoviruses are reported to engage CD46 or CAR and
α2,3-linked sialic acids to facilitate attachment.22,23 More
recently, it was established that HAdV-37 binds to
glycoproteins containing the GD1a glycan motif via its
homotrimeric fiber knob proteins.21
Sialic acid is a highly polar and negatively charged nine-
carbon monosaccharide. It is abundantly expressed on the
surface of all cell types and serves important roles in mediating
or modulating a variety of physiological and pathophysiological
processes.24 For a number of diseases, it has been proposed
that sialic acid conjugates can be used for therapeutic
intervention. However, in general terms, development of
carbohydrate-based therapeutics is challenging due to poor
pharmacological properties imparted by their high polarity,
metabolic vulnerability, and low affinity protein−carbohydrate
interactions. In addition, preparation of carbohydrates can be
both cumbersome and expensive.25 In the case of CVA24v and
HAdV-37, many of these downsides can potentially be
circumvented by the design of multivalent ligands26 intended
for topical administration, e.g., eye drops, creams, or
ointments. The design of multivalent carbohydrate ligands
offers an excellent strategy to achieve high avidity binding to
Figure 1. Design of pentavalent sialic acid conjugates. A) Schematic representation of a CVA24v particle and close-up view of one of the
pentameric sialic acid binding sites with the inhibitor modeled. Inhibitor (purple) with sialic acid highlighted (yellow). B) Schematic representation
of a HAdV-37 particle and zoom-in of one of the fiber knob proteins that contain trimeric sialic acid binding sites with the inhibitor modeled.
Inhibitor (purple) with two sialic acids in solution (gray) and three sialic acids binding (yellow). C) Schematic design of the pentavalent sialic acid
conjugates. The sialic acid residues are connected to a common core fragment via spacers of sufficient length for chelation of the pentameric
binding sites of CVA24v.
Scheme 1. Synthesis of the First and Second Sets of Pentavalent Sialic Acid Conjugates 25−28a
aReagents and conditions: a) i: molecular sieves (3 Å), 3−9, CH3CN/CH2Cl2 (2:1), rt, 30 min, ii: silver trifluoromethanesulfonate, IBr, −74 °C,
5.5 h. b) Sodium methoxide, methanol, rt, 3 h, ii: H+ ion exchange resin. c) CuSO4·5H2O, sodium ascorbate, tetrahydrofuran/H2O (1:1), 19 or 20,
50 °C, 5 h → rt, 18 h. d) i: LiOH, methanol, rt, 24 h, ii: H+ ion exchange resin.
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lectins26−28 via the “cluster glycoside effect”27 or proximity/
statistical effects.28 The cluster effect is caused by the binding
of several monosaccharide ligands to several binding sites on
the lectin, while the proximity/statistical effect is caused by a
slower off-rate of a multivalent ligand in comparison to a
monovalent ligand based on reasoning of proximity.28 Pivotal
work with Shiga and cholera toxins demonstrated that
multivalent carbohydrate ligands tailored to lectin valency
and topology produce dramatic enhancements in avidity.29,30
The bacterial AB5 Shiga toxin and radially symmetric
multivalent glycoconjugates were further used to develop and
validate a quantitative model to analyze thermodynamic
parameters of multivalent interactions.31
To date, the only substance reported to inhibit attachment
of CVA24v to cells is a 13-valent sialic acid human serum
albumin conjugate.15 For HAdV-37, we and others have shown
that trivalent and multivalent sialic acid conjugates are potent
inhibitors of HAdV-37 attachment and infection.32−34 In this
study, we developed novel pentavalent sialic acid conjugates
with the potential to act as general inhibitors of both AHC and
EKC. Such inhibitors could be applied via topical admin-
istration and used for treatment and prophylactics to alleviate
experienced symptoms and to limit transmission of these
highly contagious infections.
■ RESULTS AND DISCUSSION
Design of Pentavalent Sialic Acid Conjugates. We
previously reported that trivalent sialic acid conjugates
efficiently inhibit HAdV-37 infection of human corneal
epithelial (HCE) cells.32,33 These inhibitors were designed to
chelate the sialic acid binding sites,33 which are arranged in a
symmetric trimeric fashion in the knob domain of the HAdV-
37 twelve fibers protruding from the virus particle. We
reasoned that a similar strategy could be applied to CVA24v.
In contrast to HAdV-37, CVA24v has five sialic acid binding
sites organized over each of the twelve relatively flat surfaces of
the virus particle.18 Thus, we hypothesized that the sialic acid
binding sites of CVA24v could effectively be chelated by
pentavalent sialic acid conjugates (Figure 1A). Such
pentavalent inhibitors would also have the potential to act
on HAdV-37 by providing a high local concentration of sialic
acid upon binding to the virion by engaging one to three of the
sialic acid binding sites of the fiber knob protein with the
nonengaged sialic acids in close proximity (Figure 1B).
Perpropargylated D-glucose was selected as the core
fragment (Figure 1C),35 as it allows rapid access to pentavalent
sialic acid conjugates via “click” chemistry. Further, glucosides
can be accessed in either α- or β-configuration opening an
Figure 2. Effect of pentavalent sialic acid conjugates on CVA24v binding and infection of HCE cells and binding of 28 to CVA24v penton. A)
Virion binding in the presence of inhibitors at different concentrations at 4 °C. B) Infection at different concentrations of inhibitors at 4 °C. Error
bars are shown as the standard error of the mean (SEM). Data are presented as the % of control that is the value obtained in the absence of an
inhibitor. All experiments were performed in duplicate and for a minimum of two times. C) Structure of the 28−CVA24v complex. The observed
electron density is shown in the cage; the remaining parts of 28 have been modeled for clarity. D) Interactions of the sialic acid moiety of 28 to
amino acids in the ligand binding site of CVA24v.
ACS Chemical Biology pubs.acs.org/acschemicalbiology Articles
https://dx.doi.org/10.1021/acschembio.0c00446
ACS Chem. Biol. 2020, 15, 2683−2691
2685
interesting opportunity to study potential differences in
binding mode and potency between the two anomers. Two
spacer fragments (a polyethylene glycol (PEG) fragment and
an amide-containing alkyl fragment) were set to contain an
azide function in one end and a hydroxyl group in the other.
The length of these spacers can be tuned to study the effect of
spacer length on potency.32,33,36 The design was validated by
molecular modeling of pentavalent conjugates 25−28 (Scheme
1) to CVA24v (Figure S1). The resulting complexes were
subjected to conformational searches followed by energy
minimizations of the spacers. The final conformations were
evaluated, no steric clashes between the conjugates and
CVA24v were evident, and the carbon−carbon bond lengths
and angles showed no strain and were in agreement with
benchmark calculations (Table S1). Geometries for the α- and
β-configuration of the core were similar to slightly less strain
on the latter.
Synthesis of the First Set of Pentavalent Conjugates.
Synthesis of the pentavalent sialic acid conjugates 25−28 was
achieved in four steps from the sialic acid donors 137 and 237
(Scheme 1, SI). The core fragment 19 (α-core) was
synthesized by a two-step procedure involving microwave-
accelerated Fischer glycosylation of D-glucose using propargyl
alcohol,38 followed by O-alkylation35 with an overall yield of
23%. The spacer fragment 3 was synthesized in 95% yield by
substituting the corresponding alkyl chloride with an azide
using NaN3. Spacer fragment 4 was isolated in 62% yield by
coupling 5-amino-1-pentanol with 3-bromopropionyl chloride,
followed by azide formation. Donor 1 was sialidated using
spacer fragments 3 and 4, respectively, under promotion of
silver trifluoromethanesulfonate and IBr39 affording the
corresponding azido acetyl protected sialosides. Subsequent
O-deacetylation afforded the α-anomerically pure azido
sialosides 11 and 12, respectively, in 28% and 13% yield
over two steps. Compounds 11 and 12 were then “clicked” to
the pentapropargylated glucose cores 19 and 2035 affording the
corresponding pentavalent sialic acid methyl esters 21−24 in
41−73% yields. Subsequent saponification provided the
corresponding pentavalent sialic acid conjugates 25−28 in
86% to quantitative yields after neutralization.
Pentavalent Sialic Acid Conjugates Inhibit CVA24v
Attachment to HCE Cells. To evaluate the biological effect
of the pentavalent conjugates, binding inhibition assays were
performed.15 Compared with untreated virions, the attachment
of 35S-labeled CVA24v whole virus particles to HCE cells was
significantly attenuated when preincubated with 25−28
(Figure 2A). All inhibitors were significantly more potent
than sialic acid (IC50 ≫ 2 mM) and disialyllacto-N-tetraose
(50% reduction in binding at 2 mM).18 Inhibitors 27 and 28
both containing an amide spacer were equally potent (IC50 159
μM and 163 μM, respectively), while the PEG based inhibitors
25 and 26 showed lower potency (IC50 423 μM and 670 μM,
respectively). Thus, the inhibitors containing an amide spacer
were 3- to 4-fold more potent than inhibitors containing a PEG
spacer. All inhibitors showed similar absolute potency to the
previously reported 13-valent sialic acid conjugate.15 However,
in terms of relative ligand efficiency, the ratio of the affinity of a
ligand divided by the number of heavy atoms in the molecule,
25−28 were significantly more efficient at inhibiting CVA24v
attachment.
Pentavalent Sialic Acid Conjugates Inhibit CVA24v
Infection. To further evaluate the biological effect of the
pentavalent conjugates, infection assays were performed.32 All
four pentavalent conjugates 25−28 inhibited CVA24v virus
particles from infecting HCE cells (Figure 2B), thus
confirming the trends from the binding assays. Compounds
27−28 were 5- to 11-fold more potent than 25−26. All
inhibitors were significantly more efficient than sialic acid
monosaccharide that showed no apparent effect on infection at
4 °C (Figure 2B).
Increasing the temperature to physiological conditions (37
°C) did not significantly alter the effect of the inhibitors on the
infection (Figure S2), thus indicating the inhibitors are
efficient despite the decreased utilization of sialic acid at
increasing temperature by CVA24v.19
X-ray Crystallography Supports Binding of the
Pentavalent Sialic Acid Conjugates to CVA24v. Next,
we investigated the binding modes of 25−28 by X-ray
crystallography. Structures of all four (25−28) inhibitor−
CVA24v complexes were established with resolutions up to 1.8
Å. All structures showed clear electron density for the sialic
acid in all of the five binding sites, in addition to a couple of
the closest spacer atoms. The remaining parts of the inhibitors
were not detected, likely due to high flexibility and adaptation
of several conformations; these have been modeled into the
28−CVA24v complex (Figure 2C). The binding of 25−28 is
very similar to the binding observed for other glycan-CVA24v
structures with most of the contacts retained (Figure 2D).18
The key contributors to inhibitor binding are Ser147, Tyr250,
and Tyr145 that directly interact with the sialic acid units of
the inhibitors. Ser147 interacts with the carboxylate group of
sialic acid by donating hydrogen bonds from its side chain
hydroxyl group and its main chain amide proton. The side
chain of Tyr250 donates a hydrogen bond and a water-
mediated hydrogen bond to the C5-acetamido carbonyl
oxygen and the C4 hydroxyl group of sialic acid, respectively.
The main chain amido carbonyl of Tyr145 accepts a hydrogen
bond from the C5 acetamido-NH group of sialic acid.
Moreover, a water-mediated hydrogen bond is contributed
by the carbonyl oxygen of Pro252. To stabilize the
conformation of Tyr145, an extensive π−π stacking network
involving Tyr145, Arg254, and Phe95 appears important for
enabling contacts to the sialic acid unit. Hydrophobic contacts
are also contributed by Tyr145, Ala146, and Pro252 nonpolar
regions of the binding site. The C9 hydroxyl of the sialic acid
entity of 28 engages in intramolecular hydrogen bonding to the
carboxylate group causing the glycerol chain to adopt a
conformation that previously was observed only as a minor
conformation for other glycan-containing structures 4Q4X and
4Q4Y (Figure 2D).18 On the basis of the structural data, an
explanation to this peculiar interaction could not be
determined. The absence of electron density for the core
and spacer fragments of 25−28 is in line with previous
observations with trivalent sialic acid conjugates containing
long and flexible spacer fragments.32 In that case, successive
shortening of the spacers resulted in decreased flexibility and
increased potency, eventually resulting in detection of density
for entire molecules including spacers and core.33
Design and Synthesis of the Second Set of
Pentavalent Sialic Acid Conjugates. The second set of
compounds focused on studying the effect of spacer length on
potency. Due to their higher potency, inhibitors containing an
amide appeared more attractive for probing of a tailor-made
chelation of the sialic acid binding sites. Thus, compounds
39−42 containing successively shorter spacers and 43−46
containing longer spacers were designed (Figure 3A). Place-
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ment of the amide was probed by moving it closer to the sialic
acid residues in compounds 39−42.
Compounds 40 and 46, containing the shortest and longest
amide-containing spacers, respectively, were subjected for
further evaluation using computational methods (Figure S3
and Table S1). In an analogous manner to the first set,
modeling of 40 and 46 to CVA24v, including conformational
searches and energy minimizations, indicated that the spacers
were of sufficient length to not cause strain on the spacers, nor
were steric clashes with the amino acid backbone of the virion
evident (Table S1 and Figure S3, respectively). Thus, the
designed compounds 39−46 could be used to probe for the
optimal length required for a tailor-made chelation of the
binding sites.
To challenge the spacer length, 47 and 48 were designed
(Figure 3A). Modeling of 48 to CVA24v showed severe strain,
manifested by a large average C−C−C bond angle of 123.3°
(Figure S3 and Table S1). In addition, steric clashes occurred
between the aliphatic spacers of 48 and amino acid residues of
the virion thus indicating that, although possible, simultaneous
binding of all five sialic acid residues to the pentameric binding
sites of CVA24v is associated with significant energy costs.
Therefore, the potency of 48 should be significantly decreased
as the length of its spacers is unlikely to be of optimal length
for chelating the sialic acid binding sites. In contrast, 47 is
unlikely to act as an optimal chelator due to its extended
length, and its potency should, therefore, be reduced as
binding is likely associated with large entropic costs due to
significant loss of translational and rotational degrees of
freedom.36
Synthesis of pentavalent conjugates 39−48 was achieved in
an analogous manner to the synthesis of 25−28, with minor
Figure 3. Effect of spacer length on CVA24v and HAd-V37 binding to HCE cells and effect of 28 on the thermal stability of CVA24v. A) CVA24v
binding at 4 °C in the presence of inhibitors at different concentrations. For clarity, only representative examples from the series of spacer
optimized compounds are illustrated in the diagram. Binding inhibition data for all pentavalent sialic acid conjugates 25−28 and 39−48 are
summarized in the table, and their corresponding curves can be found in Figure S3. Error bars are shown as SEM. Data are presented as the % of
control that is the value obtained in the absence of an inhibitor. All experiments were performed in duplicate and for a minimum of two times. B)
Effect of 28 on thermal stability of CVA24v. Fluorescence curves of CVA24v with (solid black line) and without (solid gray line) 28. The dashed
lines correspond to fluorescence of 28 in the absence of CVA24v (black) and fluorescence of denatured CVA24v (gray line). The table below the
graph shows a summary of CVA24v Tm and Tm shifts (ΔTm) as measured for protein (measured by SYPRO orange) and RNA with and without
treatment of 100 μM sialic acid, pleconaril, or 28. All graphs are presented in the SI. C) HAd-V37 binding at 4 °C in the presence or absence of
inhibitors at different concentrations. Only representative examples from the complete series of spacer optimized pentavalent conjugates were
tested, in addition to trivalent sialic acid conjugateME046233 used as a control. Error bars in A and C are shown as SEM. Data are presented as the
% of control that is the value obtained in the absence of an inhibitor. All experiments were performed in duplicate and for a minimum of two times.
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modifications (SI). The use of donor 2 in combination with
decreased concentration of spacer fragment 4 proved beneficial
in the synthesis of azido sialoside 12, improving the yield to
35% over two steps. Therefore, donor 2 was used in the
synthesis of azido sialosides 13−18.
Spacer Length of the Conjugates Affects the
Inhibitory Potency against CVA24v. The inhibitory effect
of the second set of compounds was evaluated in cell binding
assays. The most potent compound 44 (IC50 157 μM) was
measured to be 1.6-fold more potent than reference compound
28 (IC50 248 μM) (Figure 3A). As expected, 47 (IC50 1.16
mM) and 48 (IC50 1.12 mM) with very long or short spacers
were the least efficient of the series proving 5.4- and 4.6-fold
less potent than 28, respectively (Figure 3A). Compounds 39−
42, containing shorter spacers, were 1.8- to 2.1-fold less potent
than 28, while compounds 43−46, containing longer spacers,
were equally or 1.4- to 1.6-fold more potent than 28 (Figure
3A and Figure S3 for dose−response curves). Thus, increased
spacer length resulted in slightly improved potency.
Correlation between anomeric configuration of the core and
potency could, however, not be demonstrated. This can
potentially be attributed to the absence of direct contacts
between the protein backbone of the virion and the spacers
and core. Further, the compounds are able to bind with either
the α- or the β-face of the core projecting toward the virion
thus rendering potential effects of core configuration to a
minimum. However, it is possible that the anomeric
configuration might play a critical role in combination with a
certain linker type and length. On the other hand, a weak
correlation between spacer length and potency was observed as
compounds with longer spacers were 3- to 4-fold more potent
than compounds with shorter spacers. However, greatly
increasing the length of the spacer was not beneficial, reflecting
the greater entropic costs of binding of a more flexible ligand.
Spacer type did not seem to affect potency as compounds 25
and 26 containing a PEG spacer were equally potent to
compounds 41 and 42 containing an amide spacer of
comparable length (Figure 3A).
Crystal structures of all inhibitor−virus complexes were
obtained and resolved as previously described; however,
similar to the 28−CVA24v complex (pdb code 6TSD),
density was only observed for the sialic acid units. Thus,
decreasing the flexibility of the conjugates by decreasing the
spacer length of 39−42 did not lead to detection of additional
electron density from the spacer(s) or core(s).
Pentavalent Sialic Acid Conjugates Provide Mild
Stabilization of the CVA24v Particle. Antiviral drugs
targeting the viral capsid have been suggested to act by
stabilization of the virus particle,40 thereby preventing (or
delaying) receptor mediated conformational changes required
for uncoating.41 Pleconaril is one of the most studied capsid-
binding molecules and is known to bind to the hydrophobic
pocket of most Enteroviruses where it replaces the hydrophobic
pocket factor (a fatty acid), which stabilizes the virus particle
preventing uncoating.42,43 Contrarily, capsid-binding molecules
could also act by destabilizing the virus particle triggering
conformational changes, resulting in early uncoating and
inactivation of the virus. To study the effect of the inhibitors
on the stability of the CVA24v particle, we performed the
Particle Stability Thermal Release Assay (PaSTRy).44 We
selected the original inhibitor 28 as a representative example of
the synthesized compounds. In addition, we selected pleconaril
and sialic acid monosaccharide as controls. The melting
temperature (Tm) of the CVA24v particle was calculated to be
48.40 °C for the proteins (Tm protein) and 50.25 °C for
release of the viral genome (Tm RNA) (Figure 3B). The
melting profile is in the same range as for other known
Enteroviruses.41 Treatment of CVA24v with the sialic acid
monosaccharide shifted the release of the viral genome to
50.96 °C indicating mild thermal stabilization (Figure S4). For
the pleconaril control, the melting temperature shifted to 51.57
°C (Figure S4), which is a relatively weak effect in comparison
to other known Enteroviruses where pleconaril had a thermal
stabilizing effect of 3−6 °C.41 Similar to pleconaril and sialic
acid, compound 28 showed a mild stabilizing effect by shifting
the Tm for release of the viral genome to 51.26 °C (Figure 3B).
This indicates that the mechanism of inhibition does not
involve destabilization of the viral capsid, and early release of
the viral genome, upon compound binding.
Pentavalent Sialic Acid Conjugates Inhibit HAdV-37
Binding to HCE Cells. To study the ability of the pentavalent
conjugates to act as general inhibitors of AHC and EKC, we
performed binding experiments using HAdV-37 and HCE
cells.23 Compared with untreated virions, the attachment of
35S-labeled HAdV-37 to HCE cells was significantly reduced
when preincubated with 28, 46, and 48 (Figure 3C). All tested
compounds were significantly more potent than the sialic acid
monosaccharide (IC50 1.2 mM)
33 and the GD1a glycan (IC50
90.8 μM).21 Compound 48 (IC50 18 nM) was roughly 3.7
orders of magnitude more potent than GD1a, while 28 (IC50
34 nM) and 46 (IC50 192 nM) proved about 2- and 11-fold
less effective than 48, respectively.21 These results were in
agreement with previous observations that multivalent sialic
acid conjugates with shorter spacers are more potent against
HAdV-37.32,33 The pentavalent conjugates were, however, not
as efficient at inhibiting HAdV-37 binding as reference
compound ME0462 (IC50 0.38 nM).
33 ME0462 has a nearly
perfect fit in the fiber knob, and our previous data indicate that
increasing valency might not improve avidity as suggested by
theoretical models.31 The relatively modest avidity gains
obtained against CVA24v are likely the result of CVA24v
engaging multiple receptors on the host cells.15,19 Nevertheless,
compounds 46 and 28 (IC50 177 μM and 248 μM against
CVA24v, respectively) proved very efficient at inhibiting
HAdV-37 supporting the prospects of developing a general
inhibitor against two of the major causes of EKC and AHC.
The potency of the compounds toward CVA24v may need
further improvement. However, administration is likely
possible in millimolar concentrations without adverse side
effects since sialic acid is nontoxic and abundantly expressed
throughout the human body. Further, repeated administration
of ME0462 in high doses to rabbits did not result in any toxic
reactions or adverse side effects.33
Spacer Length of Pentavalent Conjugates Affects
Binding to CVA24v and HAdV-37. The mechanism of
potency enhancements in multivalent ligand systems is
suggested to occur via chelation, statistical rebinding, cross-
linking, and aggregation or via a combination of these
mechanisms. An internal diffusion (bind and slide) mechanism
has also been proposed for large systems containing many
(sub)ligands.28 We were interested to study if the mechanism
of potency enhancement occurred via cross-linking and
aggregation. To study this, we performed negative staining
electron microscopy experiments with CVA24v and HAdV-37
(Figure 4). Compounds 28, 46, and 48 were selected from the
set of inhibitors as they present a compromise between spacer
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length and potency toward both CVA24v and HAdV-37.
ME0462 was selected as a control as an aggregation
mechanism seems unlikely due to the short spacers of this
compound. Compared with untreated CVA24v (Figure 4, PBS
left panel), ME0462 appears able to break up virion clusters
present in the control, thus it does not cause aggregation or
cross-linking of viral particles (Figure 4, ME0462 left panel).
In contrast, treatment with 28, 46, and 48 causes formation of
CVA24v aggregates. Moreover, the extent seems to be related
to spacer length because larger aggregates were observed after
treatment with 46 and 28 (long spacers) in comparison to 48
(Figure 4, 28, 46, and 48 of left panel). This indicates that
aggregation may be the main mechanism of potency
enhancement for the inhibitors in regards to CVA24v. It can,
therefore, not be excluded that the sialic acid density observed
in each of the five binding sites of the crystal structures
originates from more than one pentavalent molecule cross-
linking virus particles.
For HAdV-37, ME0462 showed very little to no aggregation
or cross-linking of viral particles in comparison to untreated
virions (Figure 4, PBS and ME0462 of right panel). Particles
were also predominantly monodispersed after treatment with
28 and 48 (Figure 4, 28 and 48 of right panel). However,
substantial aggregation and cross-linking were observed after
treatment with 46 (Figure 4, 46 of right panel). Thus, it is
reasonable to speculate that the main mechanism of potency
enhancement for 28 and 48 occurs via a statistical rebinding
mechanism by providing a high local concentration of sialic
acid. This can also explain the slightly increased potency of 48
in comparison to 28 as shorter spacers provide a higher
effective local concentration of ligands by a simple reasoning of
distance between the unbound ligand and binding site. For 46,
it appears that aggregation has major involvement in the
mechanism of potency enhancement. In this particular system,
aggregation does, however, not seem to cause additional
enhancement in potency in comparison to a statistical
rebinding mechanism.
In summary, we find it reasonable to speculate that the main
mechanism of inhibition for these inhibitors involves binding
to the virion thus blocking the virus from interacting with its
cognate receptor(s) on the cellular surface. This inhibition
mechanism can be complemented by, e.g., cross-linking of
virus particles where the sialic acid residues and possibly the
spacers in one compound bind to two virus particles.
The sialic acid binding sites of CVA24v and HAdV-37
are different. To further understand the binding of the
inhibitors to CVA24v and HAdV-37 and the large differences
in potency, we analyzed their respective binding sites. The
sialic acid binding sites of each virus are located in the interface
between two protomers of the biological assembly (pentamer
and trimer, respectively). The sialic acid binding sites of
HAdV-37 are more recessed and less solvent exposed because
they are located on the inner side of the fiber knobs. They are
also more rigid since there is less mobility in the loops
interacting with sialic acid.33 In CVA24v, the receptor-
engaging loops show a higher degree of mobility and form
very shallow binding sites that are solvent exposed. A
comparison of the total buried surface area (BSA) per sialic
acid entity does, however, show similar values of 160.5 Å2 for
CVA24v and 150.1 Å2 for HAdV-37. In HAdV-37, the sialic
acid moiety is recognized by direct contacts with Tyr312,
Pro317, and Lys345 and via a water-mediated hydrogen bond
to Ser344.33 A notable difference in the recognition is the
presence of a salt bridge between the carboxylate group of
sialic acid and Lys345. In the case of CVA24v, this electrostatic
interaction is absent, and the carboxylate is hydrogen bonded
to the amide of Ser147 and intramolecularly bonded to the C9
hydroxyl group of sialic acid (Figure 2D). To fully understand
these differences in recognition and their potential contribu-
tions to inhibitor potency, further studies are required.
Another underlying factor to explain the potency difference
could be that HAdV-37 exclusively relies on sialic acid glycans
for attachment, while CVA24v engages both sialic acid-
containing glycans and the coreceptor ICAM-1.19 In summary,
Figure 4. Effect of ME0462 and pentavalent sialic acid conjugates on
cross-linking and aggregation of CVA24v and HAdV-37. The left
panel shows the results of negative staining electron microscopy for
CVA24v, and the right panel shows the results for HAdV-37 in PBS
buffer or incubated with trivalent (ME0462) or pentavalent (28, 48,
46) sialic acid conjugates at a final concentration of compounds at 2
mM. Scale bars are visible at the bottom left corner for each image
and correspond to 100 nm for images with CVA24v and 200 nm for
images with HAdV-37.
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several factors seem to contribute in explaining the lower
avidity of the pentavalent conjugates toward CVA24v.
■ CONCLUSION
In this study, we have presented the first inhibitors of CVA24v
infection and demonstrated the inhibitors also effectively block
HAdV-37 binding to HCE cells. Thus, the synthesized
pentavalent sialic acid conjugates inhibit two of the major
causative agents of AHC and EKC, supporting development of
general inhibitors against these highly contagious eye
infections. Topical administration directly to the target tissue
in the eye circumvents many of the challenges facing a
compound administered orally. The sialic acid binding sites are
located on the virus surface, and the inhibitors, therefore, do
not need to permeate any cell membranes, reducing the risk of
off-target effects. Furthermore, systemic exposure is likely low
reducing the risk for toxicity or other adverse effects
originating from systemic distribution. General inhibitors are
particularly attractive in this case due to clinical difficulties in
distinguishing these infections and their causative agents. Such
inhibitors could, therefore, be applied upon development of
the first symptoms to alleviate the infections, limit the spread
in the general population, and, most importantly, to help
prevent health care-associated infections of immunocompro-
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Reḿi Caraballo − Department of Chemistry, Umeå University,
SE90187 Umeå, Sweden; orcid.org/0000-0001-5912-8429
Nitesh Mistry − Section of Virology, Department of Clinical
Microbiology, Umeå University, SE90185 Umeå, Sweden
Georg Zocher − Interfaculty Institute of Biochemistry, University
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